The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland

Prostate

Volumn 73, Issue 5, 2013, Pages 542-548

  Kluźniak, Wojciech ^a   Wokołorczyk, Dominika ^a   Kashyap, Aniruddh ^a   Jakubowska, Anna ^a   Gronwald, Jacek ^a   Huzarski, Tomasz ^a   Byrski, Tomasz ^a   Dȩbniak, Tadeusz ^a   Goła̧b, Adam ^a   Gliniewicz, Bartłomiej ^a   Sikorski, Andrzej ^a   Świtała, Jerzy ^b   Borkowski, Tomasz ^c   Borkowski, Andrzej ^c   Antczak, Andrzej ^d   Wojnar, Łukasz ^d   Przybyła, Jacek ^e   Sosnowski, Marek ^e   Małkiewicz, Bartosz ^f   Zdrojowy, Romuald ^f   Sikorska Radek, Paulina ^g   Matych, Józef ^g   Wilkosz, Jacek ^e   Rózański, Waldemar ^e   Kiś, Jacek ^h   Bar, Krzysztof ^h   Bryniarski, Piotr ⁱ   Paradysz, Andrzej ⁱ   Jersak, Konrad ^j   Niemirowicz, Jerzy ^j   Słupski, Piotr ^k   Jarzemski, Piotr ^k   Skrzypczyk, Michał ^l   Dobruch, Jakub ^l   Domagała, Paweł ^a   Akbari, Mohammad R ^m   Lubiński, Jan ^a   Narod, Steven A ^m   Cybulski, Cezary ^a   more..

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Maria Sk odowska Curie Hospital   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g Regional Hospital   (Poland)

^h University of Lublin   (Poland)

ⁱ MEDICAL UNIVERSITY OF SILESIA   (Poland)

^j Ministry of Internal Affairs and Administration Hospital   (Poland)

^k Wojewodzki Szpital im Dr J Biziela w Bydgoszczy   (Poland)

^l Department of Urology   (Poland)

^m Centre for Research on Women's Health   (Canada)

more..

Author keywords

G84E mutation; HOXB13; prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HOXB13 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PEDIGREE; POLAND; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PEDIGREE; POINT MUTATION; POLAND; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84875229518     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22594     Document Type: Article

References (25)

1. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61 (4): 212-236.
2. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA,. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336 (20): 1401-1408.
3. Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, Tulinius H, Eyfjörd JE,. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 1997; 60 (5): 1079-1084.
4. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare DM, Ponder BA, Gayther SA, Easton DF, Eeles RA,. Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators. British Association of Urological Surgeons Section of Oncology. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003; 72 (1): 1-12.
5. Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, Gulati T, Wadsworth E, Donat S, Robson ME, Ellis NA, Offit K,. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004; 10 (9): 2918-2921.
6. Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O'Brien L, Sawyer E, Hall A, Wilkinson R, Dadaev T, Goh C, Easton D, Goldgar D, Eeles R,. UKGPCS Collaborators. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients. Br J Cancer 2011; 105 (8): 1230-1234.
7. Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M, Eccles D, Axcrona K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon Y, Cajal T, Spigelman A, Teo SH, Nicolai N, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, Kyriacou K, van Asperen C, Kiemeney L, Easton DF, Eeles RA,. IMPACT Study Collaborators. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study. BJU Int 2011; 107 (1): 28-39.
8. Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, Castro E, Goh C, Govindasami K, Guy M, O'Brien L, Sawyer E, Hall A, Wilkinson R, Easton D, Goldgar D, Eeles R, Kote-Jarai Z,. UKGPCS Collaborators. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 2012; 106 (10): 1697-1701.
9. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN, Liu W,. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003; 72 (2): 270-280.
10. Seppälä EH, Ikonen T, Mononen N, Autio V, Rökman A, Matikainen MP, Tammela TL, Schleutker J,. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003; 89 (10): 1966-1970.
11. Cybulski C, Górski B, Huzarski T, Masojć B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymańska A, Szymańska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubiński J,. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004; 75 (6): 1131-1135.
12. Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, Debniak T, Masojć B, Jakubowska A, Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P, Bar K, Klijer R, Zdrojowy R, Małkiewicz B, Borkowski A, Borkowski T, Szwiec M, Narod SA, Lubiński J,. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 2006; 43 (11): 863-866.
13. Cybulski C, Górski B, Debniak T, Gliniewicz B, Mierzejewski M, Masojć B, Jakubowska A, Matyjasik J, Złowocka E, Sikorski A, Narod SA, Lubiński J,. NBS1 is a prostate cancer susceptibility gene. Cancer Res 2004; 64 (4): 1215-1219.
14. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA,. A candidate prostate cancer susceptibility gene at chromosome17p. Nat Genet 2001; 27 (2): 172-180.
15. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, Papadopoulos N, Kallioniemi OP, Burk R, Meyers D, Grönberg H, Meltzer P, Silverman R, Bailey-Wilson J, Walsh P, Isaacs W, Trent J,. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002; 30 (2): 181-184.
16. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, Marks AF, Cunningham JM, Peterson BJ, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN,. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res 2001; 61 (17): 6494-6499.
17. Xu J, Zheng SL, Carpten JD, Nupponen NN, Robbins CM, Mestre J, Moses TY, Faith DA, Kelly BD, Isaacs SD, Wiley KE, Ewing CM, Bujnovszky P, Chang B, Bailey-Wilson J, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB,. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet 2001; 68 (4): 901-911.
18. Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ, Walker AH, Spangler E, Leonard DG, Wein A, Malkowicz SB, Rebbeck TR,. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2005; 14 (4): 949-957.
19. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA,. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002; 32 (2): 321-325.
20. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y, Bizon C, Yan G, Gielzak M, Partin AW, Shanmugam V, Izatt T, Sinari S, Craig DW, Zheng SL, Walsh PC, Montie JE, Xu J, Carpten JD, Isaacs WB, Cooney KA,. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012; 366 (2): 141-149.
21. Breyer JP, Avritt TG, McReynolds KM, Dupont WD, Smith JR,. Confirmation of the HOXB13 G84E Germline Mutation in Familial Prostate Cancer. Cancer Epidemiol Biomarkers Prev 2012; 21 (8): 1348-1353.
22. Akbari MR, Trachtenberg J, Lee J, Tam S, Bristow R, Loblaw A, Narod SA, Nam RK,. Association Between Germline HOXB13 G84E Mutation and Risk of Prostate Cancer. J Natl Cancer Inst 2012; 104 (16): 1260-1262.
23. Karlsson R, Aly M, Clements M, Zheng L, Adolfsson J, Xu J, Grönberg H, Wiklund F,. A Population-based Assessment of Germline HOXB13 G84E Mutation and Prostate Cancer Risk. Eur Urol 2012; [Epub ahead of print].
24. Gronwald J, Raczyński A, Tarhoni M, Blachowski M, Huzarski T, Byrski T, Tołoczko-Grabarek A, Dȩbniak T, Cybulski C, Huzarska J, Oszurek O, Lubiński J,. Population Screening for Cancer Family Syndromes in the West Pomeranian Region of Poland. Hered Cancer Clin Pract 2006; 4 (1): 56.
25. Lin X, Qu L, Chen Z, Xu C, Ye D, Shao Q, Wang X, Qi J, Chen Z, Zhou F, Wang M, Wang Z, He D, Wu D, Gao X, Yuan J, Wang G, Xu Y, Wang G, Dong P, Jiao Y, Yang J, Ou-Yang J, Jiang H, Zhu Y, Ren S, Zhang Z, Yin C, Wu Q, Zheng Y, Turner AR, Tao S, Na R, Ding Q, Lu D, Shi R, Sun J, Liu F, Zheng SL, Mo Z, Sun Y, Xu J,. A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate 2012; DOI: 10.1002/pros.22552. [Epub ahead of print].